FILE PHOTO: A June 24, 2020 handout photo received from biotech company IDT Biologika in Dessau-Rosslau, Germany, on July 28, 2020, shows an individual dose of the filled SARS-CoV-2 vaccine candidate. Hartmut Boesener/IDT Biologika/Handout via Reuters
BERLIN (Reuters) - Unlisted biotech firm IDT Biologika has won approval from Germany's vaccine regulator to become the third German company after BioNTech and CureVac to launch human trials of an experimental coronavirus vaccine in the country.
The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
